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ABSTRACT
Objective: Carbapenems are beta-lactamase antibiotics, presently considered as most potent
agents for treatment of infections caused by Gram-negative bacilli. The aim of this study was to
determine resistance of Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella
pneumonniae as prevalent nosocomial agents to commonly used antibiotics including carbapenems
such as imipenem and meropenem.
Methodology: A total of 202 gram-negative bacilli including K.pneumoniae, P aeruginosa and
A.baumannii isolated from hospitalized patients in Milad hospital of Tehran were subject for
susceptibility testing. Susceptibility testing was performed by disk diffusion and MIC methods as
recommended by Clinical Laboratory Standards Institute (CLSI)
Results: All isolates of K. pneumonia were susceptible to imipenem and meropenem. Resistance
in non-fermenting gram-negative bacilli (NFGB) was prevalent. P.aeruginosa isolates exhibited
7.5% and 40.2% resistance to imipenem and meropenem respectively. The majority isolates of
Acinetobacter baumannii were multi-drug resistant and resistance of this organism to imipenem
and meropenem was 27.7% and 38.5% respectively.
Conclusions: Our study revealed that in spite of resistance of K.pneumoniae to commonly used
antibiotics, all isolates were susceptible to imipenem and meropeem. More than 80% isolates of
A .bammanni were resistant to commonly used antibiotics. About 40.2% isolates of P.aeruginosa
and (38.5%) isolates of A.baumannii were resistant to meropenem respectively.
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INTRODUCTION
Carbapenems was first introduced in 1980
and are now frequently used as the last choice
in treating serious infections caused by
multidrug-resistant strains of gram negative
bacilli. These antibiotics are stable to
ß-lactamase including the extended spectrum
ß -lactamase (ESBLs) and AmpC produced by
gram –negative bacilli.1-4
The carbapenems are a class of beta-
lactamase antibiotics that differ from the peni-
cillins by the substitution of a carbon atom for
a sulfur atom and by the addition of a double
bond to the five –membered ring of the peni-
cillin nucleus.5 Carbapenems bind bacterial
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peptidases, the bacterial penicillin-binding pro-
teins, which are responsible for elongation and
cross –likening the peptidoglycan of the bacte-
rial cell wall. This binding results in impair-
ment of construction of the cell wall, inhibi-
tion of cell growth frequently, cell lysis and
death. For gram-negative bacteria, it occurs in
the periplasmic space between the cell wall and
surrounding cell membrane.6
Unfortunately resistance to carbapenems
started emerging from 1990 and has been
reported in non-fermenter gram -negative
bacilli (NFGNB) worldwide over the years with
varying frequencies.1 In the SENTRY antimi-
crobial surveillance programs (SASP), 10 to
30% of P. aeruginosa strains from various coun-
tries have been found to be resistant to
imipenem. The nosocomial strains of non-fer-
menters exhibited a higher level of resistance.7
The carbapenem resistance appears to be due
to metallo- ß-lactamase. There is evidence of
the transfer of the multiple antibiotic resistance
to other species including Escheichia coli,
Enterobactr spp and Klebsiella spp. Multi-drug
resistant (including carbapenem) in gram-
negative bacteria pose a serious problem due
to the lack of therapeutic options and the po-
tential transfer of antibiotic resistance to other
virulent pathogens.5 Carbapenems available to
use in Islamic republic of Iran are meropenem
and imipenem. Information regarding preva-
lence of resistance to carbapenems in clinical
isolates in our country is very limited. There-
fore we conducted this perspective study to
evaluate antimicrobial activity of imipenem
and meropenem in Pseudomonas aerugiosa,
Acinetobacter baumannii and klebsiella
pneumoniae isolated from clinical specimens in
Milad Hospital of Tehran which is a tertiary
1000 bed hospital.
METHODOLOGY
Clinical isolates of various strains of
P.aeruginosa, A.baumannii and K.pneumoniae
from hospitalized patients in Milad hospital of
Tehran from April 2006 to November 2006
were subject of our study. The identification
of the bacteria was determined by using con-
ventional bacteriology methods. No duplicate
isolates from the same patients were included
in this study. Subcultures were prepared in
blood agar from the identified bacteria to pro-
duce pure colony isolates. From these pure
colony isolates a bacterial suspension was pre-
pared by inoculating 4-ml sterile normal saline
and adjusted the suspension to .0.5 Mc Farland
standards. The susceptibility testing was per-
formed by disk diffusion method as recom-
mended by CLSI.8 The antibiotics used were
imipenem 10µg, pipracillin/ tazobactam 100/
10µg cefepime 30µg, ceftazidime 30µg,
amikacin 30µg ciprofloxacin 5µg. The prepared
plates were then incubated at 35°C for 24
hours. Zone of inhibition were calculated by
measuring the diameter (mm) of the inhibition
growth zone. Quality control was ensured by
keeping weekly records of disk diffusion for
E.coli ATCC 25922 and Pseudomonas aeruginosa
(ATCC 27853). Minimal inhibitory concentra-
tion   (MIC) values for meropenem were deter-
mined by the E-test (AB Biodisk, Solona, Swe-
den) as recommended by manufacture. For
detection of ESBLs producing strains of
K.pnemoniae we used both screening and con-
firmatory tests by methods as recommended
by CLSI. K.pneumoniae ATCC 70603 was used
as a positive ESBLs strain.9
RESULTS
A total of 202 gram- negative bacilli includ-
ing 67 isolates of Pseudomonas aeruginosa, 65
isolates of Acintobacter baumannii and 70 iso-
lates of K;pneumoniae were tested. All strains
were isolated from hospitalized patients in
Milad hospital during six month. Milad hospi-
tal is a 1000 bed, non-teaching and the largest
hospital in Tehran. All microorganisms were
isolated from clinical specimens including tra-
cheal tube aspirates, urine, wound, blood and
other sterile body fluids. Of 70 isolates of
K.pneumoniae 56 (80%) were ESBls. All isolates
of K. pneumoniae including ESBLs were suscep-
tible to imipenem (Table-I). Resistance of
K.pneumoniae isolates against pipiracllin/
tazobactam, cefepime, ciprofloxacin and
amikacin were 47%, 67%, 40% and 55%
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respectively. Resistance in NFGNB was preva-
lent (Table-I). P.aeruginosa isolates exhibited
30%, 43%, 30%, 47% and 73% resistance to
piptacillin / tazobactam, cefepime, ciproflo-
xacin and ceftazidime respectively. The most
effective antibiotic against   P. aeuginosa was
imipenem and only 7.5% isolates of
P.aeruginosa were resistant to imipenem. The
most isolates of A.baumannii were multi-drug
resistant. Resistance of A.baumannii to
pipiracillin/tazibactam, cefepime, ciproflox-
acin, amikacn and ceftazidime was 83%, 90%,
94%, 84% and 98.5% respectively. A.baumannii
showed the lowest resistance to imipenem and
27.7% isolates of this organism were resistant
to imipenem. MIC of meropenem was ranged
from 0.5 -32µg/ml. All isolates of K.pneumoniae
were susceptible to meropenem. Of 67 isolates
of P.aeruginosa, 27 isolates (40.2%) were resis-
tant to meropenme and of 65 isolates of
A.baumanii, 25 (38.5%) were resistant to
meropenem. The majority isolates of
P.aeruginosa and A.baumannii had MIC.
>32µg/ml for meropenem. Seven strains of
A.baumannii isolates were multiple -drug resis-
tant and all of were resistant to TZP, FEP, CIP,
AN, CAZ, IMP and MEM, All strains except
one had MIC >32µg/ml for meropenem. The
majority of strains were isolated from tracheal
tube aspirates of patient hospitalized in ICU
(Table-II).
DISCUSSION
The resistance to carbapenems especially in
P.aeruginosa results from reduced levels of drug
accumulation or increased expression of pump
efflux. The resistance may also be due to the
production of metallo-ß-lactamase (MBL)
which can be chromosomally encoded or
plasmid mediated. Most of these MBL confer
resistance to not only carbapenems but also to
other ß-lactamase inhibitors such as clavulanic
acid, sulbactam and tazobactam.10 Mulridrug
–resistant including carbapenem–resistant‘
pose a serious problem due to the lack of thera-
peutic options and the potential transfer of
antibiotic resistance to more virulent pathogen.
 The increasing trend of carbapenem resistance
in Acinetobacter baumannii worldwide is a con-
cern since it limits drastically the range of
therapeutic alternatives Metallo-ß-lactamases
have been reported worldwide, especially in
Asia and western Europe, and confer resistance
to all ß-lactams except aztreonam.11,12 In our
hospital imipenem and meropenem came in to
use in 2001. Both of these antibiotics are
frequently used to treat infections caused by
multidrug–resistanant strains of Gram-
negative bacteria especially P.aeruginosa and
A baumannii.
Table-I: Frequency of antibiotic resistance in gram-negative bacilli.
Gram-negative bacilli TZP FEP CIP  AN CAZ IPM MEM
K.pneumoniae 47% 67% 40% 55% 80% 0% 0
P.aeruginosae 30% 43% 30% 47% 73% 7.5% 40.2%
 A.baumannii 83% 90% 94% 84% 98.5% 27.7% 38.5%
TZP=pipracillin/tazobactam, FEP=cefepime, CIP= ciprofloxacin,
AN=amikacin, CAZ =ceftazidime, IPM=imipenem, MEM=meropenem.
Table-II: Characteristics of 17 isolates of A.baumannii
Strain MIC Resistant Ward      Specimen
  for to other tested
MEM antibiotics
1 >32 + ICU Folly catgeter
2 >32 + ICU Tracheal aspirates
3 >32 + ICU Tracheal aspirates
4 >32 + surgical Wound
5 >32 + ICU Tracheal aspirates
6 >32 + ICU Tracheal aspirates
7 >32 + surgical Wound
8 >32 + Internal Ear
9 >32 + Internal Chest tube
10 >32 + ICU Folly catheter
11 >32 + ICU Tracheal tube
12 >32 + ICU Folly catgeter
13 >32 + ICU Tracheal tube
14 >8 + ICU Folly catgeter
15 >32 + ICU Tracheal tube
16 >32 + ICU Folly catgeter
17 >32 + ICU Tracheal tube
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There is a limited literature available regard-
ing the prevalence of resistance to carbapenems
in various clinical isolates in our country. Re-
cent study from Tehran hospitals showed that
all isolates of K.pneumonia were susceptible to
imipenem and meropenem, which is the same
as our study.13 In our study resistance to
pipracillin/tazobactam, cefepime, ciprofloxa-
cin and amikacin showed moderate action
against K.pneumoniae. Resistance among
NFGNB was prevalent. This study documented
imipenem resistance of 7.5% and 27.7% among
67 isolates of P.aeruginosa and 65 isolates of A.
baumanni respectively. In other study by
Ahngaranzadeh-Rezaee and co-workers,
29.3% hospital  isolates of P.aeruginosa  in
Tehran were resistant to imipeneme.14 Other
study by Moniri et al in a teaching hospital
located in Kashan in center of Iran, they have
reported a high frequency resistance of
P.aeruginosa to imipenem. It also shows a con-
siderably higher prevalence of resistance
among A.baumanni which is different from
other studies.15 In a study performed in India
overall 36.4% of nonfermenters were resistant
to imipenem and 42% of P.aeruginosa and
18.5% A, baumanni were imipenem resistant.10
This disturbing situation could be attributed to
the increased use of antibiotics which has to
be controlled by strict antibiotics policy. Regu-
lar monitoring and documentation of carbap-
enem resistance is therefore crucial in devel-
oping world to control infections due to these
bacteria in patients admitted to hospitals.
CONCLUSIONS
In conclusion, our study highlights the
increasing incidence of carbapenem resistance
in Gram-negative non-fermenting bacilli.
Including P.aeruginosa and A,baumannii. There
is a further need for investigation and epide-
miology studies in this field.
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